Cross-disease immune cells atlas reveals the similarities and differences of cell characteristics and interactions in rheumatic diseases - Scorecard - MDSpire

Cross-disease immune cells atlas reveals the similarities and differences of cell characteristics and interactions in rheumatic diseases

  • By

  • Liqing Ding

  • Qiming Meng

  • Ding Bao

  • Bingying Dai

  • May 13, 2026

Share

Clinical Scorecard: Immune Cell Atlas Across Rheumatic Diseases Uncovers Commonalities and Variations in Cellular Characteristics and Interactions

At a Glance

CategoryDetail
Condition
Key MechanismsExpand to include specific interactions and roles of immune cells.
Target Population
Care Setting

Key Highlights

  • distinct_myeloid_activation_states

Guideline-Based Recommendations

Diagnosis

    Management

    • I
    • n
    • c
    • l
    • u
    • d
    • e
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • t
    • h
    • e
    • r
    • a
    • p
    • i
    • e
    • s
    • o
    • r
    • i
    • n
    • t
    • e
    • r
    • v
    • e
    • n
    • t
    • i
    • o
    • n
    • s
    • b
    • a
    • s
    • e
    • d
    • o
    • n
    • i
    • m
    • m
    • u
    • n
    • e
    • d
    • y
    • s
    • r
    • e
    • g
    • u
    • l
    • a
    • t
    • i
    • o
    • n
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Individuals diagnosed with rheumatic diseases.

        Focus on personalized treatment approaches based on immune cell dysregulation patterns.

        Clinical Best Practices

        • add

        Related Resources & Content

        Original Source(s)

        Cross-disease immune cells atlas reveals the similarities and differences of cell characteristics and interactions in rheumatic diseases

        • by Liqing Ding, Qiming Meng, Ding Bao, Bingying Dai

        • May 13, 2026

        Related Content

        The risk association between systemic lupus erythematosus and glaucoma: a systematic review and meta-analysis

        Correction: Clinical significance of erythrocyte sedimentation rate-based stratification in a large retrospective SLE cohort

        Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

        Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.